The ALS Association has awarded a $1.5M grant to Robert Miller, Director of the Forbes Norris MDA/ALS Research Center at Sutter Health’s California Pacific Medical Center in San Francisco, to support a Phase II trial of NP001 in ALS. NP001 is an anti-inflammatory drug under development by Neuraltus Pharmaceuticals that regulates activated, inflammatory macrophages. The clinical trial, expected to begin later this year, will aim to confirm evidence from a previous Phase II study of potential clinical benefits of NP001 in ALS patients. Importantly, the trial will examine two biomarkers of inflammation identified in the prior study in greater detail – interleukin-18 and lipopolysaccharide (LPS). The $1.5M in funding from the ALS Association combined with the $1.2M in funding from Neuraltus will help accelerate clinical trial initiation and clinical development of NP001.
Click here to read more.